| Rational of the use of aliskiren in hypertension and beyond. | |
| | |
MedLine Citation:
|
PMID: 20019651 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Arterial hypertension is an independent risk factor for cardiovascular diseases and one of the major causes for mortality worldwide. Drugs, that control hypertension effectively are therefore needed to reduce hypertension induced morbidity and mortality. The inhibition of the renin-angiotensin-aldosterone-system (RAAS) is one target to control blood pressure in these patients. The new direct renin inhibitor aliskiren is one new substance on the market to inhibit the RAAS effectively by suppression of the plasma renin activity, which inhibits the RAAS at its rate-limiting step. Therefore, aliskiren in monotherapy and in combination might yield beneficial effects for the patients. Nevertheless, blood pressure lowering has to be combined with a reduction of target organ damage for all drug classes prescribed to patients with hypertension. Therefore, we review here the major effects of this new drug not only in regard to hypertension but also in regard to target organ damage reduction and possible changes in morbidity and mortality, which future trials will investigate. |
| | |
Authors:
|
D Westermann; K Savvatis; H P Schultheiss; C Tsch?pe |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Minerva cardioangiologica Volume: 57 ISSN: 0026-4725 ISO Abbreviation: Minerva Cardioangiol Publication Date: 2009 Dec |
Date Detail:
|
Created Date: 2009-12-18 Completed Date: 2010-04-23 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0400725 Medline TA: Minerva Cardioangiol Country: Italy |
Other Details:
|
Languages: eng Pagination: 761-72 Citation Subset: IM |
Affiliation:
|
Department of Cardiology and Pneumology,Charit? School of Medicine, Campus Benjamin Franklin, Berlin, Germany. dirk.westermann@web.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Amides
/
administration & dosage,
therapeutic use* Angiotensin II / physiology Angiotensin II Type 1 Receptor Blockers / administration & dosage, therapeutic use Antihypertensive Agents / administration & dosage, therapeutic use* Biphenyl Compounds / administration & dosage, therapeutic use Cardiovascular Diseases / mortality, prevention & control* Diabetic Nephropathies / drug therapy* Diuretics / administration & dosage, therapeutic use Drug Therapy, Combination Europe / epidemiology Fumarates / administration & dosage, therapeutic use* Germany / epidemiology Heart Failure / drug therapy*, mortality Humans Hydrochlorothiazide / administration & dosage, therapeutic use Hypertension / blood, drug therapy*, epidemiology Japan / epidemiology Prevalence Protein Precursors / physiology Randomized Controlled Trials as Topic Receptors, Cell Surface / physiology Renin / antagonists & inhibitors*, blood, physiology Renin-Angiotensin System* / drug effects, physiology Risk Factors Tetrazoles / administration & dosage, therapeutic use Time Factors World Health Organization |
| Chemical | |
Reg. No./Substance:
|
0/Amides; 0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 0/Biphenyl Compounds; 0/Diuretics; 0/Fumarates; 0/Protein Precursors; 0/Receptors, Cell Surface; 0/Tetrazoles; 0/aliskiren; 0/prorenin receptor; 11128-99-7/Angiotensin II; 138402-11-6/irbesartan; 58-93-5/Hydrochlorothiazide; EC 3.4.23.15/Renin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Use of the levonorgestrel-releasing intrauterine system: an Austrian perspective.
Next Document: Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF ...